Table 3.
Interaction of TCF7L2 and APC 1822 variants and CRC and CRA risk in the NHS
| Cancer Cases | Controls | Multivariate OR1 (95% CI) |
P-int2 | ||
|---|---|---|---|---|---|
| TCF7L2 | APC 1822 | ||||
| GG | Asp | 50 (28.3) | 129 (29.3) | 1.00 (Ref) | |
| GT+TT | Asp | 55 (31.1) | 128 (29.1) | 1.13 (0.69 – 1.86) | |
| GG | Asp+Val | 42 (23.7) | 88 (20.0) | 1.23 (0.68 – 2.22) | |
| GT+TT | Asp+Val | 30 (17.0) | 95 (21.6) | 0.76 (0.42 – 1.37) | |
| 0.40 | |||||
| Adenoma Cases | Controls |
Multivariate OR2 (95% CI) |
P-int | ||
| TCF7L2 | APC 1822 | ||||
| GG | Asp | 154 (30.5) | 147 (29.3) | 1.00 (Ref) | |
| GT+TT | Asp | 129 (25.5) | 139 (27.7) | 0.91 (0.63 - 1.33) | |
| GG | Asp+Val | 109 (21.6) | 117 (23.4) | 0.94 (0.64 – 1.37) | |
| GT+TT | Asp+Va1 | 113 (22.4) | 98 (19.6) | 1.21 (0.80 – 1.84) | |
| 0.10 |
1
Logistic regression adjusted for family history of colon cancer, pack years smoked, body mass index (BMI), post-menopausal hormone (PMH) use, aspirin intake, physical activity, alcohol intake, total folate consumption, and red meat consumption.
2
P-int: P-value from LRT comparing the model with main effects for each polymorphism to the model including crosstabulated indicator variables.